GPGrossPatternRESEARCH SYSTEM
SEC CHECK OPERATIONAL
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

IMDX · Dec 31, 2025

Insight Molecular Diagnostics Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration

State dimensions

Filing0001642380-26-000004General Corporate
Capex intensity67thOwn-history percentile · N=9
Evidence method

Level · gp.fundamentals.capex_revenue_ratio

78.55% · OPTIONAL · VALID

Operating cash generation83thOwn-history percentile · N=12
Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-547.08% · OPTIONAL · VALID

Revenue growth63thOwn-history percentile · N=8
Evidence method

Yoy · gp.fundamentals.revenue

115.58% · CORE · VALID

Inventory pressureRAWCurrent state valid · history insufficient
Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

11.00% · OPTIONAL · NOT_ENOUGH_HISTORY

Gross margin67thOwn-history percentile · N=12
Evidence method

Level · gp.fundamentals.gross_margin

56.67% · CORE · VALID

Operating margin83thOwn-history percentile · N=12
Evidence method

Level · gp.fundamentals.operating_margin

-1260.76% · CORE · VALID

R&D intensity8thOwn-history percentile · N=12
Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

392.11% · OPTIONAL · VALID

SBC intensity8thOwn-history percentile · N=12
Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

54.72% · OPTIONAL · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History15 statesHistory building
Dec 31, 20220/6 normalizedLevel 3Mar 31, 20230/5 normalizedLevel 3Jun 30, 20230/5 normalizedLevel 3Sep 30, 20230/5 normalizedLevel 3Dec 31, 20230/7 normalizedLevel 3Mar 31, 20240/7 normalizedLevel 3Jun 30, 20240/7 normalizedLevel 3Sep 30, 20240/8 normalizedLevel 3Dec 31, 20245/8 normalizedLevel 3Mar 31, 20255/8 normalizedLevel 3Jun 30, 20255/8 normalizedLevel 3Sep 30, 20256/8 normalizedLevel 3Dec 31, 20257/8 normalizedLevel 3Mar 31, 20267/8 normalizedLevel 3Jun 30, 20267/8 normalizedLevel 3
Period transition

What moved in the state?

Capex Intensity Decreased
Previous
403.85%
Current
78.55%
Delta
-325.30%
Cash Generation Increased
Previous
-1731.54%
Current
-547.08%
Delta
1184.46%
Growth Decreased
Previous
126.09%
Current
115.58%
Delta
-10.51%
Inventory Pressure Decreased
Previous
181.15%
Current
11.00%
Delta
-170.16%
Margin Increased
Previous
53.46%
Current
56.67%
Delta
3.21%
Profitability Increased
Previous
-4249.23%
Current
-1260.76%
Delta
2988.47%
R And D Intensity Decreased
Previous
1491.54%
Current
392.11%
Delta
-1099.43%
Sbc Intensity Decreased
Previous
200.38%
Current
54.72%
Delta
-145.66%
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.
Research Graph

Related governed research

Transitioned To · IMDX Fundamental State →Transitioned To · IMDX Fundamental State →Transitioned To · IMDX CAPEX_INTENSITY_DECREASED →Transitioned To · IMDX CASH_GENERATION_INCREASED →Transitioned To · IMDX GROWTH_DECREASED →Transitioned To · IMDX INVENTORY_PRESSURE_DECREASED →Transitioned To · IMDX MARGIN_INCREASED →Transitioned To · IMDX PROFITABILITY_INCREASED →Transitioned To · IMDX R_AND_D_INTENSITY_DECREASED →Transitioned To · IMDX SBC_INTENSITY_DECREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.